Abstract: Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the cuter cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.

Abstract: Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the cuter cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.

Abstract: Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the outer cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.

Abstract: The present invention is concerned with oligonucleotides that can be used as in the amplification and detection of Epstein Barr Virus (EBV) nucleic acid, in particular RNA-specific sequences. Furthermore a method for the diagnosis of EBV associated malignant and non-malignant diseases is provided. The oligonucleotides according to the present invention are specifically suited for the detection of EBV gene expression in circulating peripheral blood cells, in human (tumor) tissue samples and thin sections thereof using “in solution” amplification or “in situ” amplification techniques and in other biological samples potentially containing EBV-infected cells.

Abstract: The invention relates to a peptide reagent comprising peptides immunochemically reactive with antibodies to the human cytomegalovirus (CMV). New antibodies directed to said peptides or fragments thereof are also part of the invention. Also cell lines capable of producing monoclonal antibodies are part of the invention. The invention also relates to a method for the detection of CMV or antibodies directed against CMV in a test fluid and a test kit to be used when applying the said detection methods. Detection of CMV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to said peptide, which have the characteristics of detecting both native and denatured DMV proteins are also part of said invention.

Abstract: The present invention is concerned with oligonucleotides that can be used as in the amplification and detection of Epstein Barr Virus (EBV) nucleic acid, in particular RNA-specific sequences. Furthermore a method for the diagnosis of EBV associated malignant and non-malignant diseases is provided. The oligonucleotides according to the present invention are specifically suited for the detection of EBV gene expression in circulating peripheral blood cells, in human (tumor) tissue samples and thin sections thereof using “in solution” amplification or “in situ” amplification techniques and in other biological samples potentially containing EBV-infected cells.

Abstract: The invention relates to a peptide reagent comprising peptides immunochemically reactive with antibodies to the human cytomegalovirus (CMV). New antibodies directed to said peptides or fragments thereof are also part of the invention. Also cell lines capable of producing monoclonal antibodies are part of the invention. The invention also relates to a method for the detection of CMV or antibodies directed against CMV in a test fluid and a test kit to be used when applying the said detection methods. Detection of CMV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to said peptide, which have the characteristics of detecting both native and denatured DMV proteins are also part of said invention.

Abstract: The invention relates to peptides or fragments thereof which are immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. New antibodies directed to said peptides or fragments thereof are also part of the invention.

Abstract: The invention relates to a peptide or fragment thereof which is immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. A new monoclonal antibody directed to said peptide or fragment thereof is also part of the invention. The invention also relates to a method for the detection of EBV or anti-EBV antibodies in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the said detection methods. Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal; directed to the said peptide, which have the characteristics of detecting both native and denatured intact, functional EBNA-1 protein is also part of said invention.

Abstract: The invention relates to peptides or fragments thereof which are immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. New antibodies directed to said peptides or fragments thereof are also part of the invention.The invention also relates to a method for the detection of EBV or antibodies directed against EBV in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the said detection methods.Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to the said peptide, which have the characteristics of detecting both native and denatured EBV-EA protein is also part of said invention.

Abstract: The present invention is directed to diagnostic reagents for the detection of antibodies against the Epstein Barr Virus and a method for the detection of antibodies to the Epstein Barr Virus in a sample.The diagnostic reagents according to the invention comprise a combination of at least part of an Epstein Barr viral structural protein, preferably a Epstein Barr VCA-protein or an Epstein Barr MA protein, and at least part of an Epstein Barr EBNA protein. Preferably, the VCA-protein is VCA-p18 protein, the MA-protein is MA-gp350/220 protein and the EBNA-protein is EBNA-1 protein.It has been found that the combination of a VCA-protein or a MA-protein, and an EBNA protein, into a single diagnostic assay yields an EBV-antibody detection method with greater sensitivity and accuracy than current methods.